Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H23NO.BrH |
| Molecular Weight | 362.304 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=IQVABVYNAOOBIJ-UHFFFAOYSA-N
InChI=1S/C19H23NO.BrH/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17;/h2-11,18-19H,12-15H2,1H3;1H
| Molecular Formula | C19H23NO |
| Molecular Weight | 281.392 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01146 | https://www.ncbi.nlm.nih.gov/pubmed/42012 | https://www.ncbi.nlm.nih.gov/pubmed/1912125
Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
CNS Activity
Originator
Approval Year
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4156058/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENYLPYRALINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. | 1977 |
|
| [Antimycobacterial antihistaminics]. | 1989 Aug |
|
| Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. | 1991 Aug 15 |
|
| Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. | 2001 Jan 1 |
|
| Sensitive determination of pethidine in body fluids by surface ionization organic mass spectrometry. | 2001 Jul 5 |
|
| Treatment of urethral sphincter mechanism incompetence in 11 bitches with a sustained-release formulation of phenylpropanolamine hydrochloride. | 2002 Sep 28 |
|
| Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. | 2006 |
|
| Transition metal complexes of quinolino[3,2-b]benzodiazepine and quinolino[3,2-b]benzoxazepine: synthesis, characterization, and antimicrobial studies. | 2007 |
|
| Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives. | 2008 Dec 15 |
|
| Development and validation of LC-MS/MS method for the determination of cyproheptadine in several pharmaceutical syrup formulations. | 2009 Dec 5 |
|
| Development and validation of an LC-MS/MS confirmatory method for residue analysis of cyproheptadine in urine of food-producing animals. | 2009 Mar 25 |
|
| Application of dummy molecularly imprinted solid-phase extraction in the analysis of cyproheptadine in bovine urine. | 2009 May |
|
| Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
Brain tissue was obtained at autopsy on 18 Japanese patients with chronic schizophrenia. The brain tissues were weighed, homogenized and centrifuged. The specific 3H-mepyramine binding to the brain tissues reached equilibrium values within 20 min after incubation at 25°C. Inhibition of the specific component of the 3H-mepyramine binding by Diphenylpyraline was then studied. The H1 antagonist diphenylpyraline (Ki=4.1nM) was potent competitors for the specific binding of 3H-mepyramine.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:07:44 GMT 2023
by
admin
on
Sat Dec 16 06:07:44 GMT 2023
|
| Record UNII |
1QG9Y7X51O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5807-87-4
Created by
admin on Sat Dec 16 06:07:44 GMT 2023 , Edited by admin on Sat Dec 16 06:07:44 GMT 2023
|
PRIMARY | |||
|
m4640
Created by
admin on Sat Dec 16 06:07:44 GMT 2023 , Edited by admin on Sat Dec 16 06:07:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID50206797
Created by
admin on Sat Dec 16 06:07:44 GMT 2023 , Edited by admin on Sat Dec 16 06:07:44 GMT 2023
|
PRIMARY | |||
|
1QG9Y7X51O
Created by
admin on Sat Dec 16 06:07:44 GMT 2023 , Edited by admin on Sat Dec 16 06:07:44 GMT 2023
|
PRIMARY | |||
|
71586817
Created by
admin on Sat Dec 16 06:07:44 GMT 2023 , Edited by admin on Sat Dec 16 06:07:44 GMT 2023
|
PRIMARY |